案例报告:多学科的管理患者的惰的系统性乳腺细胞瘤和耐火症状
Matthew J Hamilton1, Loren W Greene2, Lauren M Madigan3
1Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
Frontiers in allergy
|November 4, 2024
概括
系统性乳腺细胞瘤 (SM) 是一种罕见的血液疾病,涉及乳腺细胞的积累. 这项案例研究强调了阿瓦普利提尼布作为晚期MS的潜在治疗方法,显示出超出支持性护理之外的前景.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 系统性乳腺细胞瘤 (SM) 是一种罕见的血液学疾病,其特征是克隆性乳腺细胞增殖.
- 临床表现因介质释放 (软性SM) 或组织透 (高级SM) 而有所不同.
- 激活KIT突变,特别是D816V,导致超过90%的成年SM病例.
研究的目的:
- 描述一个年轻的成年男性患有全身性巨细胞瘤的病例,呈现骨质疏松症,反流和过敏反应.
- 为了说明SM的诊断和管理挑战,需要采用多学科方法.
- 讨论Avapritinib,一种选择性KIT D816V抑制剂,在管理先进的SM中的作用.
主要方法:
- 病例报告详细说明了临床表现,诊断工作和治疗开始.
- 审查目前最好的支持性护理和SM的先进疗法.
- 讨论作为KIT D816V抑制剂的阿瓦普利提尼布的作用机制.
主要成果:
- 这位患者出现了骨质疏松症,反流,以及过敏反应史,表明SM.
- 仅仅支持性护理不足以控制患者的疾病进展.
- 阿瓦普利提尼布最初是针对KIT D816V突变的向治疗.
结论:
- 系统性乳腺细胞瘤需要一个全面的,多学科的方法,以获得最佳的患者结果.
- 像阿瓦普利提尼布这样的向疗法为管理晚期MS提供了一个有希望的途径,特别是在不耐支持性护理的病例中.
- 对SM的新疗法和治疗管道的进一步研究至关重要.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
240
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
240
Myocarditis III: Medical Management
2
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
Inflammatory Bowel Disease IV: Pharmacological Management
116
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
116
Myocarditis IV: Nursing Management
2
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
2
Pulmonary Tuberculosis V
170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170
Chronic Pancreatitis II: Collaborative Care
70
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
70


